All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Could radiotherapeutic approaches be a promising new treatment option for myeloma?
Featured:
Sikander AilawadhiThe Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Sikander Ailawadhi, Mayo Clinic, Jacksonville, US, answers the question: Could radiotherapeutic approaches be a promising new treatment option for myeloma?
Dr Ailawadhi discusses the use of radiopharmaceutical agents for the treatment of myeloma, specifically focusing on a novel agent, CLR 131, which is being tested in patients with relapsed/refractory disease. Key takeaways: in the most recent cohort, divided dosing across two days and a second part one week later was able to stop disease progression for 3-3.5 months, in this small patient cohort. Dr Ailawadhi concludes by discussing what setting he believes these agents may be utilized in, noting this may represent an exciting new option for patients with myeloma.
Could radiotherapeutic approaches be a promising new treatment option for myeloma?
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?